639 related articles for article (PubMed ID: 15759279)
21. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
22. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene.
Wybranietz WA; Gross CD; Phelan A; O'Hare P; Spiegel M; Graepler F; Bitzer M; Stähler P; Gregor M; Lauer UM
Gene Ther; 2001 Nov; 8(21):1654-64. PubMed ID: 11895004
[TBL] [Abstract][Full Text] [Related]
23. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo.
Zender L; Kühnel F; Köck R; Manns M; Kubicka S
Cancer Gene Ther; 2002 Jun; 9(6):489-96. PubMed ID: 12032659
[TBL] [Abstract][Full Text] [Related]
24. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy.
Steffens S; Frank S; Fischer U; Heuser C; Meyer KL; Dobberstein KU; Rainov NG; Kramm CM
Cancer Gene Ther; 2000 May; 7(5):806-12. PubMed ID: 10830728
[TBL] [Abstract][Full Text] [Related]
25. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport.
Xiong F; Xiao S; Yu M; Li W; Zheng H; Shang Y; Peng F; Zhao C; Zhou W; Chen H; Fang L; Chamberlain JS; Zhang C
BMC Neurosci; 2007 Jul; 8():50. PubMed ID: 17617925
[TBL] [Abstract][Full Text] [Related]
26. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
[TBL] [Abstract][Full Text] [Related]
27. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
28. Intercellular spread of GFP-VP22.
Aints A; Dilber MS; Smith CI
J Gene Med; 1999; 1(4):275-9. PubMed ID: 10738560
[TBL] [Abstract][Full Text] [Related]
29. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.
Rosenfeld ME; Feng M; Michael SI; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 1995 Dec; 1(12):1571-80. PubMed ID: 9815958
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
31. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
32. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines.
Wybranietz WA; Prinz F; Spiegel M; Schenk A; Bitzer M; Gregor M; Lauer UM
J Gene Med; 1999; 1(4):265-74. PubMed ID: 10738559
[TBL] [Abstract][Full Text] [Related]
33. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells.
Yang J; Liu TJ; Lu Y
Curr Eye Res; 2007 Jan; 32(1):33-42. PubMed ID: 17364733
[TBL] [Abstract][Full Text] [Related]
34. Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting.
Aints A; Güven H; Gahrton G; Smith CI; Dilber MS
Gene Ther; 2001 Jul; 8(14):1051-6. PubMed ID: 11526452
[TBL] [Abstract][Full Text] [Related]
35. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
37. [Effect of adenovirus-mediated TK/GCV gene therapy in combination with TNF-alpha against murine bladder cancer cells in vitro].
Shi XH; Tan WL; Zhu WH; Liang ZK; DU YJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):750-3. PubMed ID: 18504196
[TBL] [Abstract][Full Text] [Related]
38. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
Ai Zheng; 2004 Jul; 23(7):788-93. PubMed ID: 15248913
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes.
Guan J; Ma L; Wei L
Chin Med J (Engl); 2001 Feb; 114(2):147-51. PubMed ID: 11780195
[TBL] [Abstract][Full Text] [Related]
40. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
